Investment analysts at WallachBeth boosted their target price on shares of Ironwood Pharmaceuti (NASDAQ: IRWD) Ironwood Pharmaceuti opened at 14.14 on Wednesday. Ironwood Pharmaceuti has a 52-week low of $10.01 and a 52-week high of $15.92. The stock?s 50-day moving average is currently $11.67. The company?s market cap is $1.518 billion. Ironwood Pharmaceuti last posted its quarterly earnings results on Tuesday, January 15th. The company reported ($0.41) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.49) by $0.08. The company had revenue of $27.00 million for the quarter, compared to the consensus estimate of $16.17 million. During the same quarter in 2012, the company posted ($0.07) earnings per share. Ironwood Pharmaceuti?s revenue was down 16.1% compared to the same quarter last year. Analysts expect that Ironwood Pharmaceuti will post $-0.74 EPS for the current fiscal year.
A number of other analysts have also recently weighed in on IRWD. Analysts at Mizuho raised their price target on shares of Ironwood Pharmaceuti from $22.00 to $24.00 in a research note to investors on Wednesday. They now have a ?buy? rating on the stock. Separately, analysts at UBS AG downgraded shares of Ironwood Pharmaceuti from a ?neutral? rating to a ?sell? rating in a research note to investors on Wednesday. They now have a $11.50 price target on the stock, down previously from $14.00. Finally, analysts at Ladenburg Thalmann raised their price target on shares of Ironwood Pharmaceuti from $16.00 to $18.00 in a research note to investors on Tuesday. They now have a ?buy? rating on the stock. Six investment analysts have rated the stock with a buy rating, four have given a hold rating, and two have issued a sell rating to the stock. Ironwood Pharmaceuti has a consensus rating of ?overweight? and an average price target of $15.45. Ironwood Pharmaceuticals, Inc., formerly Microbia, Inc. is an entrepreneurial pharmaceutical company that discovers, develops and focuses to commercialize medicines targeting important therapeutic needs.